Targeting BCL|2 in B|cell lymphomas

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic ...

Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins are key regulators of the intrinsic, mitochondrial apoptotic pathway.

Targeting BCL-2 in B-cell lymphomas - PubMed

The B-cell leukemia/lymphoma-2 (BCL-2) family of proteins governs the intrinsic pathway of mitochondrial apoptosis. Dysregulation of BCL-2 ...

Targeting the Bcl-2 Family in B Cell Lymphoma - Frontiers

This review comprehensively examines each member of the Bcl-2 protein family, defining their contribution to B cell lymphomagenesis through mouse models.

Targeting the Bcl-2 Family in B Cell Lymphoma - PubMed

Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma subtypes share ...

Targeting BCL-2 in B-cell lymphomas | Blood - ASH Publications

A highly potent and selective oral BCL-2 antagonist, venetoclax, was approved in chronic lymphocytic leukemia, where it has proven to be highly active.

B-cell lymphoma 2 (Bcl-2) protein family

... cell proliferation [6]. Prosurvival Bcl-2 family proteins are therefore tractable drug targets for the development of novel anti-cancer therapies, as well ...

B-cell lymphoma 2 family members and sarcomas

Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements.

B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer ...

This review discusses the role of Bcl-2 in cancer development; it could be exploited as a potential target for developing novel therapeutic strategies.

Perspective Targeting BCL-2 in B-cell lymphomas - ScienceDirect.com

Conclusions. The recent approval of venetoclax has demonstrated that BCL-2 inhibition is an important new approach in treating B-cell lymphomas.

Therapeutic development and current uses of BCL-2 inhibition

B-cell lymphoma 2 (BCL2) is a key protein regulator of apoptosis. It is variably highly expressed in many hematological malignancies, ...

Targeting the Inhibition of B-Cell Lymphoma 2 Protein for the ...

Thus, inhibition of the Bcl-2 protein has emerged as a viable biological target for the potential development of novel anti-cancer therapy.

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

The B-cell lymphoma/leukemia 2 (BCL-2) family of proteins has attracted the attention of cancer biologists since the cloning of BCL-2 more than 25 years ago ...

Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical ...

In this review, we focus on the expression levels of the anti-apoptotic proteins in cervical cancer tissues and how to possibly target them with BH3-mimetics.

Specific interactions of BCL-2 family proteins mediate sensitivity to ...

BCL-2, BCL-XL and MCL-1 are important therapeutic targets in diffuse large B-cell lymphoma. To investigate the roles of the main anti ...

BCL2-Family Dysregulation in B-Cell Malignancies - Frontiers

Targeting BCL-2 in B-cell lymphomas. Blood (2017) 130:1081–8. doi: 10.1182/blood-2017-04-737338. PubMed Abstract | CrossRef Full Text | Google Scholar. 22 ...

Dual targeting of the DNA damage response pathway and BCL-2 in ...

Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, ...

B-Cell Lymphoma 2 Inhibitor - an overview | ScienceDirect Topics

A B-Cell Lymphoma 2 Inhibitor is a type of compound that targets and reduces the activity of anti-apoptotic Bcl-2 proteins, which are often overexpressed in ...

[PDF] Targeting BCL-2 in B-cell lymphomas. | Semantic Scholar

The history of targeting BCL-2 in B-cell lymphomas is reviewed, recent data on venetoclax used as monotherapy and in combination with monoclonal antibodies, ...

BCL2 apoptosis regulator | B-cell lymphoma 2 (Bcl-2) protein family

The role of Bcl-2 in cancers and other important conditions (for example autoimmune diseases and schizophrenia) makes it an attractive target for pharmaceutical ...

BCL-2 protein family: attractive targets for cancer therapy | Apoptosis

Studies using inducible gene deletion revealed that a broad range of cancer cells, including AML [167], MYC driven B cell lymphomas [135], T ...